Rejoni Showcases FDA-Approved Juveena® Hydrogel System at AAGL 2026 Global Congress in Boston Alongside Pivotal Trial Results Published in Fertility and Sterility

[#item_full_content]BURLINGTON, Mass.–(BUSINESS WIRE)–Rejoni, Inc., a commercial-stage women’s health company focused on uterine health, today announced its participation in the AAGL 55th Global Congress on Minimally Invasive Gynecologic Surgery (MIGS), taking place Nov. 13-16, 2026, at the Hynes Convention Center in Boston. At the meeting, results from the Juveena pivotal trial will be featured in an oral presentation during the Scientific Sessions. The trial results are published in Fertility and Sterility, th

Leave a Reply

Your email address will not be published. Required fields are marked *